These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 36178208)

  • 1. Addressing Atropisomerism in the Development of Sotorasib, a Covalent Inhibitor of KRAS G12C: Structural, Analytical, and Synthetic Considerations.
    Lanman BA; Parsons AT; Zech SG
    Acc Chem Res; 2022 Oct; 55(20):2892-2903. PubMed ID: 36178208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Approaches to Synthesis and Isolation of Enantiomerically Pure Biologically Active Atropisomers.
    Carlsson AC; Karlsson S; Munday RH; Tatton MR
    Acc Chem Res; 2022 Oct; 55(20):2938-2948. PubMed ID: 36194144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KRAS Inhibitor Resistance in
    Suzuki S; Yonesaka K; Teramura T; Takehara T; Kato R; Sakai H; Haratani K; Tanizaki J; Kawakami H; Hayashi H; Sakai K; Nishio K; Nakagawa K
    Clin Cancer Res; 2021 Oct; 27(20):5697-5707. PubMed ID: 34365406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonclinical Safety Profile of Sotorasib, a KRAS
    Ishida K; Werner JA; Davies R; Fan F; Thomas B; Wahlstrom J; Lipford JR; Monticello T
    Int J Toxicol; 2021 Oct; 40(5):427-441. PubMed ID: 34137282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BCL-X
    Khan S; Wiegand J; Zhang P; Hu W; Thummuri D; Budamagunta V; Hua N; Jin L; Allegra CJ; Kopetz SE; Zajac-Kaye M; Kaye FJ; Zheng G; Zhou D
    J Hematol Oncol; 2022 Mar; 15(1):23. PubMed ID: 35260176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atropisomerism in Drug Discovery: A Medicinal Chemistry Perspective Inspired by Atropisomeric Class I PI3K Inhibitors.
    Perreault S; Chandrasekhar J; Patel L
    Acc Chem Res; 2022 Sep; 55(18):2581-2593. PubMed ID: 36069734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beyond KRAS(G12C): Biochemical and Computational Characterization of Sotorasib and Adagrasib Binding Specificity and the Critical Role of H95 and Y96.
    Mahran R; Kapp JN; Valtonen S; Champagne A; Ning J; Gillette W; Stephen AG; Hao F; Plückthun A; Härmä H; Pantsar T; Kopra K
    ACS Chem Biol; 2024 Oct; 19(10):2152-2164. PubMed ID: 39283696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments.
    Koga T; Suda K; Fujino T; Ohara S; Hamada A; Nishino M; Chiba M; Shimoji M; Takemoto T; Arita T; Gmachl M; Hofmann MH; Soh J; Mitsudomi T
    J Thorac Oncol; 2021 Aug; 16(8):1321-1332. PubMed ID: 33971321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sotorasib: a treatment for non-small cell lung cancer with the KRAS G12C mutation.
    Zheng X; Luo J; Liu W; Ashby CR; Chen ZS; Lin L
    Drugs Today (Barc); 2022 Apr; 58(4):175-185. PubMed ID: 35412531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacophoric analogs of sotorasib-entrapped KRAS G12C in its inactive GDP-bound conformation: covalent docking and molecular dynamics investigations.
    Oyedele AK; Ogunlana AT; Boyenle ID; Ibrahim NO; Gbadebo IO; Owolabi NA; Ayoola AM; Francis AC; Eyinade OH; Adelusi TI
    Mol Divers; 2023 Aug; 27(4):1795-1807. PubMed ID: 36271195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sotorasib for previously treated colorectal cancers with KRAS
    Fakih MG; Kopetz S; Kuboki Y; Kim TW; Munster PN; Krauss JC; Falchook GS; Han SW; Heinemann V; Muro K; Strickler JH; Hong DS; Denlinger CS; Girotto G; Lee MA; Henary H; Tran Q; Park JK; Ngarmchamnanrith G; Prenen H; Price TJ
    Lancet Oncol; 2022 Jan; 23(1):115-124. PubMed ID: 34919824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of Cinchona Alkaloids in the Enantio- and Diastereoselective Synthesis of Axially Chiral Compounds.
    Portolani C; Centonze G; Righi P; Bencivenni G
    Acc Chem Res; 2022 Dec; 55(24):3551-3571. PubMed ID: 36475607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Stereoselective Total Synthesis of Axially Chiral Naphthylisoquinoline Alkaloids.
    Tajuddeen N; Feineis D; Ihmels H; Bringmann G
    Acc Chem Res; 2022 Sep; 55(17):2370-2383. PubMed ID: 35980132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ABCB1 limits brain exposure of the KRAS
    Loos NHC; Retmana IA; Li W; Martins MLF; Lebre MC; Sparidans RW; Beijnen JH; Schinkel AH
    Pharmacol Res; 2022 Apr; 178():106137. PubMed ID: 35192958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Properties of Configurationally Stable Atropoenantiomers in Macrocyclic Natural Products and the Chrysophaentin Family.
    Bewley CA; Sulikowski GA; Yang ZJ; Bifulco G; Cho HM; Fullenkamp CR
    Acc Chem Res; 2023 Feb; 56(4):414-424. PubMed ID: 36731116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aryne Atropisomers: Chiral Arynes for the Enantiospecific Synthesis of Atropisomers and Nanographene Atropisomers.
    Coquerel Y
    Acc Chem Res; 2023 Jan; 56(2):86-94. PubMed ID: 36595619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of a Covalent Inhibitor of KRAS
    Lanman BA; Allen JR; Allen JG; Amegadzie AK; Ashton KS; Booker SK; Chen JJ; Chen N; Frohn MJ; Goodman G; Kopecky DJ; Liu L; Lopez P; Low JD; Ma V; Minatti AE; Nguyen TT; Nishimura N; Pickrell AJ; Reed AB; Shin Y; Siegmund AC; Tamayo NA; Tegley CM; Walton MC; Wang HL; Wurz RP; Xue M; Yang KC; Achanta P; Bartberger MD; Canon J; Hollis LS; McCarter JD; Mohr C; Rex K; Saiki AY; San Miguel T; Volak LP; Wang KH; Whittington DA; Zech SG; Lipford JR; Cee VJ
    J Med Chem; 2020 Jan; 63(1):52-65. PubMed ID: 31820981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atropisomerism in the Pharmaceutically Relevant Realm.
    Basilaia M; Chen MH; Secka J; Gustafson JL
    Acc Chem Res; 2022 Oct; 55(20):2904-2919. PubMed ID: 36153960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mercapturate pathway metabolites of sotorasib, a covalent inhibitor of KRAS
    Werner JA; Davies R; Wahlstrom J; Dahal UP; Jiang M; Stauber J; David B; Siska W; Thomas B; Ishida K; Humphreys WG; Lipford JR; Monticello TM
    Toxicol Appl Pharmacol; 2021 Jul; 423():115578. PubMed ID: 34004237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDA Approval Summary: Sotorasib for KRAS G12C-Mutated Metastatic NSCLC.
    Nakajima EC; Drezner N; Li X; Mishra-Kalyani PS; Liu Y; Zhao H; Bi Y; Liu J; Rahman A; Wearne E; Ojofeitimi I; Hotaki LT; Spillman D; Pazdur R; Beaver JA; Singh H
    Clin Cancer Res; 2022 Apr; 28(8):1482-1486. PubMed ID: 34903582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.